{
  "id": 19348372,
  "title": "FDA warns GLP-1 drugs may pose risk of rare condition that causes vision loss",
  "url": "https://urgent.news/2026/11/10/fda-warns-glp-1-drugs-may-pose-risk-of-rare-condition-that-causes",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-10T14:43:49.000Z",
  "source": {
    "name": "Ars Technica Health",
    "slug": "ars-technica-health",
    "url": "https://arstechnica.com/health/2026/11/glp-1-drugs-may-increase-risk-of-vision-loss-from-rare-condition-fda-warns/"
  },
  "original_language": "en",
  "account": "The Food and Drug Administration has issued a warning that GLP-1 receptor agonist drugs, including Ozempic, Wegovy, Zepbound, and Mounjaro, may raise the risk of a rare eye condition known as non-arteritic anterior ischemic optic neuropathy, or NAION. This condition arises from reduced blood flow to the optic nerve, resulting in swelling, cell death, and ultimately, permanent vision loss. The exact mechanism by which these drugs could trigger NAION remains unclear. Despite its rarity, occurring in two to 10 individuals per 100,000 in the general population, the difficulty in determining a definitive link is amplified by the common risk factors associated with GLP-1 drug usage. These factors include diabetes, cardiovascular disease, hypertension, hypercholesterolemia, metabolic syndrome, and obstructive sleep apnea.",
  "summary": "The risk appears small and data is mixed, but FDA wants patients to be aware.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 8,
    "also_reported_by": [
      {
        "outlet": "STAT News",
        "title": "STAT+: FDA warns GLP-1 drugs carry potential risk of rare eye condition",
        "url": "https://urgent.news/2026/11/09/stat-fda-warns-glp-1-drugs-carry-potential-risk-of-rare-eye-condition",
        "published": "2026-11-09T15:56:55.000Z"
      },
      {
        "outlet": "Medical Xpress",
        "title": "GLP-1 drugs show lower obesity-related cancer risk than insulin, but not all diabetes treatments",
        "url": "https://urgent.news/2026/11/09/glp-1-drugs-show-lower-obesity-related-cancer-risk-than-insulin-but",
        "published": "2026-11-09T18:20:04.000Z"
      },
      {
        "outlet": "Winnipeg Free Press",
        "title": "FDA adds rare vision-loss warning to popular GLP-1 drugs",
        "url": "https://urgent.news/2026/11/09/fda-adds-rare-vision-loss-warning-to-popular-glp-1-drugs",
        "published": "2026-11-09T20:21:53.000Z"
      },
      {
        "outlet": "The Hill",
        "title": "FDA warns of rare 'eye stroke' risk from GLP-1 drugs",
        "url": "https://urgent.news/2026/11/09/fda-warns-of-rare-eye-stroke-risk-from-glp-1-drugs",
        "published": "2026-11-09T21:33:48.000Z"
      },
      {
        "outlet": "CBS News",
        "title": "FDA warns of rare vision-loss side effect from GLP-1 drugs",
        "url": "https://urgent.news/2026/11/10/fda-warns-of-rare-vision-loss-side-effect-from-glp-1-drugs",
        "published": "2026-11-10T00:09:36.000Z"
      },
      {
        "outlet": "The Hindu Health",
        "title": "FDA adds rare vision-loss warning to popular obesity, diabetes drugs",
        "url": "https://urgent.news/2026/11/10/fda-adds-rare-vision-loss-warning-to-popular-obesity-diabetes-drugs",
        "published": "2026-11-10T05:42:48.000Z"
      },
      {
        "outlet": "CNBC",
        "title": "FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound",
        "url": "https://urgent.news/2026/11/10/fda-warns-of-vision-loss-risk-linked-to-popular-glp-1-drugs-like",
        "published": "2026-11-10T07:52:40.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}